Allstate Corp Buys Shares of 6,274 IQVIA Holdings Inc. $IQV

Allstate Corp purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 6,274 shares of the medical research company’s stock, valued at approximately $1,192,000.

Several other large investors also recently modified their holdings of IQV. Asset Dedication LLC boosted its position in IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 168 shares during the last quarter. Trust Co. of Toledo NA OH bought a new stake in shares of IQVIA during the 2nd quarter valued at about $39,000. J.Safra Asset Management Corp grew its stake in IQVIA by 208.6% during the second quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after purchasing an additional 169 shares during the period. Rothschild Investment LLC increased its holdings in IQVIA by 85.5% in the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after purchasing an additional 124 shares in the last quarter. Finally, NewSquare Capital LLC lifted its stake in IQVIA by 185.3% in the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after buying an additional 189 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of NYSE IQV opened at $241.28 on Thursday. The company has a market capitalization of $41.09 billion, a PE ratio of 33.10, a PEG ratio of 2.38 and a beta of 1.36. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The stock’s 50 day moving average price is $228.51 and its 200-day moving average price is $204.88. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same period last year, the business posted $2.84 earnings per share. IQVIA’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on IQV. TD Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. Citigroup upped their price objective on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a report on Wednesday, October 29th. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and raised their target price for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. Finally, Barclays set a $230.00 price target on IQVIA in a research note on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.19.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. The trade was a 12.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is owned by insiders.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.